CCO Treatment Updates
Melanoma Treatment Update
Genetics and Molecular Pathogenesis of Melanoma: Current Understanding
|
Module 1 of 4
|
|
|
|
 New insights into genetic predisposition to melanoma, the pathogenesis of the disease, and its evasion of immune system response. Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify inherited genetic factors that increase an individual’s risk of developing melanoma
- Summarize current hypotheses and supporting data relating to disruptions of key signaling pathways in melanoma
- Review the role of immune surveillance defects in melanoma oncogenesis
- Discuss possible future implications of progress in understanding melanoma pathogenesis for prognosis and treatment
|
Melanoma Diagnosis and Staging: Evolving Practice
|
Module 2 of 4
|
Program Director:
John M. Kirkwood, MD
- Jeffrey E. Gershenwald, MD, FACS
|
|
|
Jeffrey E. Gershenwald, MD, FACS, provides an overview and update on current and emerging approaches to characterizing melanoma in individual patients, including pathologic staging and sentinel lymph node biopsy. Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the role of sentinel lymph node biopsy in the staging of melanoma
- Discuss the tumor, node, metastases classifications of melanoma and the prognoses associated with the various TNM categories
- Explain how subgroups in the stage III grouping differ regarding nodal involvement and prognosis
- Describe new molecular profiling technologies for melanoma patients and the relationship between molecular prognostic factors and outcome
|
Treatment of Melanoma: Current Best Practice
|
Module 3 of 4
|
Program Director:
John M. Kirkwood, MD
|
|
Review current therapeutic options for patients with melanoma across the continuum of progression, from the localized to metastatic. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe current recommended clinical practice for excision of localized melanomas and patient selection for sentinel lymph node biopsy
- Discuss current evidence regarding the efficacy of interferon alfa adjuvant therapy in preventing relapse and extending survival in patients with high-risk melanoma
- Summarize data on the efficacy of chemoimmunotherapy in patients with advanced melanoma
- Identify novel agents for systemic therapy of melanoma currently being evaluated in clinical trials
|
Exploring New Directions in Melanoma Treatment
|
Module 4 of 4
|
Program Director:
John M. Kirkwood, MD
|
|
Keith Flaherty, MD, reviews cutting edge research for treatment of advanced melanoma, including immunotherapies, antibodies, and chemotherapeutic combinations. Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify agents under investigation in melanoma that target signaling pathways that are dysregulated due to mutations in BRAF
- Discuss the current status of clinical development of these agents
- Describe cell-based immunomodulatory therapy approaches for enhancing immune response to melanoma
- Summarize recent data on their efficacy
- Describe possible approaches for enhancing tumor suppressor gene function in melanoma
- Discuss targeted immunologic agents under study in melanoma and the current status of their clinical development
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|